Drugs / Nitroglycerin
last change Aug 2026 re-read 2 minutes ago

Nitroglycerin

Developed for
coronary artery disorder · Raynaud disease · non-small cell lung carcinoma · erectile dysfunction · hypertensive disorder · heart failure · hypotensive disorder · intracerebral hemorrhage
+54 more · ischemic stroke · pancreatitis · acute kidney injury · arterial disorder · autonomic dysreflexia · chronic obstructive pulmonary disease · chronic ulcer of skin · coronary vasospasm · COVID-19 · diabetic neuropathy · disease of bone structure · end stage renal failure · esophageal disorder · female infertility · infectious disease with sepsis · ischemic disease · left ventricular failure · lung cancer · metastatic malignant neoplasm in the brain · myocardial disorder · myocardial infarction · myocardial ischemia · myofascial pain syndrome · nosocomial infection · obstructive sleep apnea syndrome · osteoporosis · periodontal disorder · peripheral arterial disease · phlebitis · placenta disorder · preeclampsia · prosthesis-related infectious disease · pulmonary arterial hypertension · pulmonary edema · rectal cancer · scleroderma · sickle cell disease · symptomatic heart failure · tendinitis · ulcer of anus and rectum · acute myocardial infarction · acute pancreatitis · acute tubulointerstitial nephritis · arterial occlusion · breast disorder · disease of the tendon · intracranial vasospasm · nonobstructive coronary artery disease · pregnancy disorder · pulmonary hypertension · pulmonary hypertension, neonatal · rectal disorder · ST-elevation myocardial infarction · stroke disorder
Investigated by
MediQuest Therapeutics · National Heart, Lung, and Blood Institute (NHLBI) · University of California, San Francisco · Vanderbilt University · Assiut University · Danish Headache Center
+87 more · Seoul National University Hospital · Bayer · Futura Medical Developments Ltd. · Instituto de Cardiologia de Santa Catarina · Minia University · Thomas Jefferson University · University of Edinburgh · 424 General Military Hospital · Aarhus University Hospital · Ain Shams University · Alison Huang, MD · Anticancer Fund, Belgium · Aristotle University Of Thessaloniki · Augusta University · Beni-Suef University · Bristol-Myers Squibb · Cairo University · Copenhagen University Hospital, Hvidovre · Covis Pharma S.à.r.l. · Cure Therapeutics · Deborah Heart and Lung Center · Duke University · Dutch Society of Physicians for Pulmonology and Tuberculosis · EUROHEAD · Erasmus Medical Center · First Affiliated Hospital of Wannan Medical College · Forest Laboratories · Frisius Medisch Centrum · GF Strong Rehabilitation Centre · HealthPartners Institute · Hospital General Universitario Elche · Hvidovre University Hospital · Icahn School of Medicine at Mount Sinai · Indiana University · Instituto Nacional de Cardiologia Ignacio Chavez · Johns Hopkins University · King Edward Medical University · King's College London · Kolding Sygehus · Komar University of Science and Technology · Kyoto University · Liang Bing · M.D. Anderson Cancer Center · Maastricht Radiation Oncology · Mansoura University · Merck Sharp & Dohme LLC · Mohammad Ali Nazarinia · Muhammad Aamir Latif · NHS Lothian · Nanjing First Hospital, Nanjing Medical University · National Cancer Institute of Mexico · National Center for Research Resources (NCRR) · National Cheng-Kung University Hospital · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · National Institute of Cancerology · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Institute on Aging (NIA) · National Institutes of Health Clinical Center (CC) · Novel Anti-Infective Technologies, LLC · Orthopaedic Trauma Association · Pfizer · Procris Pharmaceuticals · Rabin Medical Center · Reliable Cancer Therapies · Richmond Pharmacology Limited · Shiraz University of Medical Sciences · Simon Fraser University · South London and Maudsley NHS Foundation Trust · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Tri-Service General Hospital (TSGH) · US Department of Veterans Affairs · University College London Hospitals · University College, London · University Hospital Birmingham · all 93 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) NITROLINGUAL 1997-01-10 fda.gov
Approved US (FDA) NITROGLYCERIN 1981-05-28 fda.gov

Trials 94 · started per year

today
US approved 1981
1
1
1
1
6
3
4
6
2
4
1
3
4
5
6
5
7
2
5
2
2
6
3
2
6
6
1981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 03 trials
Phase 0 NCT05239013 May 2022 → Mar 2023 arterial disorder Thomas Jefferson University Unknown No outcome recorded
Phase 0 NCT06172998 Apr 2022 → Apr 2024 obstructive sleep apnea syndrome Xu J Unknown No outcome recorded
Phase 0 NCT04155476 Dec 2019 → Mar 2020 peripheral arterial disease Deborah Heart and Lung Center Unknown No outcome recorded
Phase 19 trials
Phase 1 NCT07004764 Nov 2026 → Sep 2027 expected Johns Hopkins University Not yet recruiting No outcome recorded
Phase 1 NCT07431294 Oct 2026 → May 2027 expected coronary artery disorder Bayer Not yet recruiting No outcome recorded
Phase 1 NCT04008732 Nov 2017 → Apr 2018 erectile dysfunction Futura Medical Developments Ltd. Completed No outcome recorded
Phase 1 NCT02617550 Nov 2015 → May 2016 coronary artery disorder Bayer Completed No outcome recorded
Phase 1 NCT02425566 Apr 2015 → Jul 2026 overdue hypertensive disorder Vanderbilt University Active not recruiting No outcome recorded
Phase 1 NCT01407107 Jan 2011 → Oct 2015 rectal cancer University of Texas Southwestern Medical Center Completed No outcome recorded
Phase 1 NCT00686231 May → Dec 2008 University of California, San Francisco Completed No outcome recorded
Phase 1 NCT01616485 Mar → May 2004 erectile dysfunction VIVUS LLC Completed No outcome recorded
Phase 1 NCT00223717 Jan 2001 → Jan 2017 hypertensive disorder Vanderbilt University Completed No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT05442931 May → Oct 2022 Minia University Unknown No outcome recorded
Phase 1/2 NCT04685031 Feb → Apr 2021 phlebitis Komar University of Science and Technology Unknown No outcome recorded
Phase 1/2 NCT02577718 Nov 2015 → Jun 2016 nosocomial infection, prosthesis-related infectious disease Novel Anti-Infective Technologies, LLC Completed No outcome recorded
Phase 221 trials
Phase 2 NCT05635851 Dec 2026 → Feb 2028 expected autonomic dysreflexia, spinal cord injury Simon Fraser University Not yet recruiting No outcome recorded
Phase 2 NCT07682454 Aug 2026 → Feb 2029 expected hepatocellular carcinoma University of California, San Francisco Not yet recruiting No outcome recorded
Phase 2 NCT06289946 Mar 2024 → Mar 2025 coronary artery disorder Thomas Jefferson University Unknown No outcome recorded
Phase 2 NCT03259165 Dec 2017 → Dec 2021 heart failure, pulmonary edema Indiana University Terminated No outcome recorded
Phase 2 NCT03357731 Nov 2017 → May 2019 left ventricular failure Bristol-Myers Squibb Completed No outcome recorded
Phase 2 NCT02714205 Apr 2017 → Mar 2022 Alison Huang, MD Completed No outcome recorded
Phase 2 NCT02688270 Jun → Dec 2016 Raynaud disease Covis Pharma S.à.r.l. Completed No outcome recorded
Phase 2 NCT02801305 Jun 2016 → Jan 2017 chronic ulcer of skin Mohammad Ali Nazarinia Completed No outcome recorded
Phase 2 NCT03235921 Mar 2016 → Aug 2017 Assiut University Unknown No outcome recorded
Phase 2 NCT02495467 May 2015 → Jul 2016 erectile dysfunction Futura Medical Developments Ltd. Completed No outcome recorded
Phase 2/34 trials
Phase 2/3 NCT06785337 Feb → Oct 2025 overdue chronic obstructive pulmonary disease Beni-Suef University Recruiting No outcome recorded
Phase 2/3 NCT01155167 Jul 2010 → Aug 2011 University of California, San Francisco Completed No outcome recorded
Phase 2/3 NCT00253331 Nov 2004 → Sep 2005 Raynaud disease MediQuest Therapeutics Completed No outcome recorded
Phase 2/3 NCT01279551 Jan 2004 → Sep 2010 University of Roma La Sapienza Completed No outcome recorded
Phase 312 trials
Phase 3 NCT04766151 Jan → Dec 2021 coronary vasospasm 424 General Military Hospital Unknown No outcome recorded
Phase 3 NCT04321967 Aug 2019 → Nov 2022 gynecomastia disorder Icahn School of Medicine at Mount Sinai Withdrawn No outcome recorded
Phase 3 NCT03158532 Jul 2017 → Oct 2021 Instituto de Cardiologia de Santa Catarina Completed No outcome recorded
Phase 3 NCT02343276 Feb → Aug 2015 Instituto de Cardiologia de Santa Catarina Completed No outcome recorded
Phase 3 NCT01864252 Jan 2014 → Oct 2018 myocardial disorder University College, London Completed No outcome recorded
Phase 3 NCT01132391 Jan → Apr 2009 ulcer of anus and rectum Hospital General Universitario Elche Completed No outcome recorded
Phase 3 NCT00493415 Jun 2007 → Jul 2008 infectious disease with sepsis Frisius Medisch Centrum Completed No outcome recorded
Phase 3 NCT00419419 Dec 2006 → ? Raynaud disease, scleroderma MediQuest Therapeutics Completed No outcome recorded
Phase 3 NCT00266669 Dec 2005 → May 2006 Raynaud disease MediQuest Therapeutics Completed No outcome recorded
Phase 3 NCT00121901 Oct 2004 → Oct 2007 pancreatitis Hvidovre University Hospital Completed No outcome recorded
Phase 417 trials
Phase 4 NCT07391501 Feb 2026 → Nov 2028 expected internal hemorrhoid Ying Zhu Not yet recruiting No outcome recorded
Phase 4 NCT07044232 Oct 2025 → Sep 2026 expected intracerebral hemorrhage Aarhus University Hospital Recruiting No outcome recorded
Phase 4 NCT07083063 Sep 2025 → Jul 2027 expected pancreatitis National Cheng-Kung University Hospital Recruiting No outcome recorded
Phase 4 NCT06682260 Feb → Nov 2025 heart failure Copenhagen University Hospital, Hvidovre Completed No outcome recorded
Phase 4 NCT05687669 Jan → Apr 2023 preeclampsia Assiut University Completed No outcome recorded
Phase 4 NCT06428669 Aug 2022 → Aug 2025 University of Virginia Unknown No outcome recorded
Phase 4 NCT03809065 Jan → May 2019 hypotensive disorder Cairo University Completed No outcome recorded
Phase 4 NCT03777605 Dec 2018 → Dec 2020 intermediate coronary syndrome Kolding Sygehus Unknown No outcome recorded
Phase 4 NCT03304496 Mar 2018 → Mar 2019 coronary artery disorder Instituto Nacional de Cardiologia Ignacio Chavez Suspended No outcome recorded
Phase 4 NCT03305848 Aug 2017 → Apr 2019 esophageal disorder HealthPartners Institute Completed No outcome recorded
Phase not applicable25 trials
NCT07603037 Jul 2026 → Jul 2027 expected acute respiratory failure, aortic disorder, hypertensive disorder First Affiliated Hospital of Wannan Medical College Not yet recruiting No outcome recorded
NCT07159334 Aug → Dec 2025 overdue hemorrhoid King Edward Medical University Recruiting No outcome recorded
NCT06925763 Apr 2025 overdue disease of bone structure, periodontal disorder Minia University Not yet recruiting No outcome recorded
NCT06637956 Jan → Jun 2024 Muhammad Aamir Latif Completed No outcome recorded
NCT05855954 May 2023 → Aug 2025 overdue acute kidney injury Nanjing First Hospital, Nanjing Medical University Recruiting No outcome recorded
NCT06238882 Feb 2023 → Dec 2026 expected metastatic malignant neoplasm in the brain, non-small cell lung carcinoma National Cancer Institute of Mexico Recruiting No outcome recorded
NCT05443061 Sep 2022 → Mar 2025 ischemic disease Seoul National University Hospital Completed No outcome recorded
NCT07214129 Mar 2022 → Mar 2023 pulmonary arterial hypertension Mansoura University Completed No outcome recorded
NCT04686760 Nov 2020 → Dec 2021 COVID-19 University of Lahore Completed No outcome recorded
NCT04564521 Sep 2020 → Jun 2024 retinoblastoma Seoul National University Hospital Unknown No outcome recorded
Also used as a comparator or background therapy in 73 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT03059316 Comparator Jun 2016 → Apr 2017 Cairo University Completed No outcome recorded
Phase 0 NCT04017845 Comparator Apr 2015 → May 2017 adenomatous colon polyp, colorectal cancer Lewai Sharki Abdulaziz, MSc PhD Completed No outcome recorded
Phase 14 trials
Phase 1 NCT04594629 Comparator Nov 2020 → May 2021 pulmonary hypertension Ain Shams University Unknown No outcome recorded
Phase 1 NCT00841594 Comparator Feb 2009 Raynaud disease MediQuest Therapeutics Completed No outcome recorded
Phase 1 NCT00700518 Comparator Jun → Nov 2008 Raynaud disease Procris Pharmaceuticals Completed No outcome recorded
Phase 1 NCT00513994 Comparator Aug → Oct 2007 MediQuest Therapeutics Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT04220281 Comparator Dec 2019 → Feb 2020 Ain Shams University Terminated No outcome recorded
Phase 21 trial
Phase 2 NCT03478332 Comparator Jun 2017 → May 2020 coronary artery disorder Affiliated Hospital of Changchun University of Chinese Medicine Unknown No outcome recorded
Phase 2/34 trials
Phase 2/3 NCT06107465 Comparator Nov 2023 → Jun 2024 pulmonary edema Alexandria University Unknown No outcome recorded
Phase 2/3 NCT03716050 Comparator Jan 2018 → Mar 2019 Wake Forest University Health Sciences Terminated No outcome recorded
Phase 2/3 NCT00953303 Comparator Jan 2009 → Sep 2011 heart failure Hebei Medical University Completed No outcome recorded
Phase 2/3 NCT00419549 Comparator Oct 2003 → Sep 2005 acute pancreatitis All India Institute of Medical Sciences Terminated No outcome recorded
Phase 316 trials
Phase 3 NCT06912139 Comparator Apr → Jun 2023 coronary vasospasm University of Medicine and Pharmacy "Victor Babes" Timisoara Completed No outcome recorded
Phase 3 NCT06301880 Comparator Jan 2022 → Jan 2023 Damascus University Completed No outcome recorded
Phase 3 NCT05837403 Background Oct 2020 → Jul 2022 ulcer of anus and rectum Al-Kindy College of Medicine Completed No outcome recorded
Phase 3 NCT03689946 Background Mar 2019 → Jan 2023 cardiovascular disorder, hyperlipidemia Cedars-Sinai Medical Center Completed No outcome recorded
Phase 3 NCT03787030 Comparator Dec 2018 → Feb 2019 Hospital General Universitario Elche Completed No outcome recorded
Phase 421 trials
Phase 4 NCT06859554 Comparator Mar → May 2025 anal spasm Hafiz Muhammad Hamza Completed No outcome recorded
Phase 4 NCT05616455 Comparator Oct 2021 → Mar 2022 ulcer of anus and rectum Treviso Regional Hospital Completed No outcome recorded
Phase 4 NCT04661709 Background Mar 2021 → Mar 2023 intermediate coronary syndrome Guang'anmen Hospital of China Academy of Chinese Medical Sciences Unknown No outcome recorded
Phase 4 NCT04270279 Background Dec 2020 → Aug 2021 coronary artery disorder Guang'anmen Hospital of China Academy of Chinese Medical Sciences Unknown No outcome recorded
Phase 4 NCT04270071 Background Dec 2020 → Oct 2021 coronary artery disorder Guang'anmen Hospital of China Academy of Chinese Medical Sciences Unknown No outcome recorded
Phase not applicable24 trials
NCT05741229 Comparator Jan → Dec 2024 pulmonary hypertension, neonatal, respiratory system disorder Alexandria University Completed No outcome recorded
NCT05952011 Background Aug 2023 → Feb 2025 Ain Shams University Completed No outcome recorded
NCT05718310 Comparator Nov 2022 → Dec 2024 migraine disorder IRCCS National Neurological Institute "C. Mondino" Foundation Unknown No outcome recorded
NCT05590520 Comparator Nov 2022 → Nov 2023 ulcer of anus and rectum Pak Emirates Military Hospital Unknown No outcome recorded
NCT07585201 Comparator Sep 2022 → Feb 2023 hypotensive disorder Zagazig University Completed No outcome recorded

Evidence & citations 31 cited values

Every value below carries the sentence it was read from. 181 sources stand behind the page.

FieldValueCited text
Known as nitroglycerin “Those who tolerate all formulations will enter the 12-week treatment phase and be randomly assigned to one of five groups: 0.3 mg sublingual nitroglycerin tablet, 0.6 mg of the...” PMID 24010992 Sep 2013
130

“The ideal treatment would be a safe, inexpensive, quickly effective medication without significant side effects that could be administered without sedation or extensive...” NCT03305848

“milrinone (Baxter Pharmaceuticals, Ahmedabad, India) 10 mg in 20 ml of dextrose 5%, nitroglycerin (Caspian Tamin Pharmaceutical, Guilan, Iran) 10 mg in 20 ml of normal saline,...” NCT06301880

“A Randomized, Phase II, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Response Study of an Aqueous Topical Formulation of Nitroglycerin, IMX-150, in the Treatment of...” NCT00641953

“On the third day, under patient safety, Nitroglycerin will be pumped into the OSA patients equipped with PSG and ECG monitoring in a safe dose to prevent endothelial dysfunction.” NCT06172998

“using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).” NCT00512759

Nitroglycerin (Nitrostat) is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.” NCT04008732

“Guideline- driven standard medical treatment including statins,antiplatelet drugs(aspirin or Clopidogrel ), anti-ischemic drugs (Nitroglycerin)” NCT03102502

“Application of nitroglycerin (glyceryl trinitrate) ointment with perianal administration is a widely used treatment for chronic anal fissure.” PMID 22810476 Aug 2012

Nitroglycerin patches have been found to cause alleviation of pain especially when used in conjuction with morphine.” NCT00375362

“we maintain the patient's central venous pressure below 10 mmHg by adjusting the posture and pumping nitroglycerin.” NCT05855954

“Local nitroglycerin (NTG) was successfully used as a vasodilator to facilitate cannulation of the radial artery.” NCT04002544

“Topical Nitroglycerin Prior to Trans-radial Coronary Angiography: a Phase 2, Randomized Controlled Trial” NCT06289946

“treatment with either topical nitroglycerin or botulinum toxin is effective as an alternative to surgery” NCT05590520

“Intravenous nitroglycerin at low doses (approximately 10 doses ranging from 0.05-100 ng/min)” NCT00838695

“SL nitroglycerin (400 ucg) will be given every 5 minutes, a total of three times.” NCT03259165

“Nitropaste is a topical agent that contains 2% nitroglycerin.” NCT06428669

“Furosemide; torsemide; nitroglycerin; dopamine; Dobutamine” NCT00953303

“oral nitroglycerin tablets (0.5 mg twice daily)” NCT07074834

Nitroglycerin: sublingual necessary.” NCT01502943

nitroglycerinNCT00803634

NCT00577304

NCT02327793

NCT05443061

NCT03716050

NCT00001716

NCT00586261

NCT06925763

NCT00480753

NCT06785337

NCT03357731

NCT05442931

NCT00842023

NCT03304496

NCT07682454

NCT07603037

NCT03849183

NCT06238882

NCT04220281

NCT03917004

NCT03605095

NCT06682260

NCT05837403

NCT05952011

NCT01996436

NCT05682716

NCT02425566

NCT04017845

NCT02115724

NCT00252421

NCT06912139

NCT07083063

NCT00335010

NCT02413268

NCT00253331

NCT05741229

NCT04321967

NCT04564521

NCT01279551

NCT02209636

NCT00810381

NCT01407107

NCT01155167

NCT04594629

NCT00043719

NCT00090558

NCT01920074

NCT00886405

NCT00901758

NCT00093886

NCT00447928

NCT02059018

NCT00712894

NCT03235921

NCT07391501

NCT02617550

NCT00419419

NCT00896311

NCT02343276

NCT00266669

NCT06107465

NCT02583633

NCT01999517

NCT01608880

NCT03777605

NCT04685031

NCT02254252

NCT00000503

NCT00686231

NCT01210378

NCT02577718

NCT02083055

NCT04155476

NCT01104597

NCT00223717

NCT07585201

NCT05718310

NCT02961946

NCT03809065

NCT07431294

NCT00934427

NCT03689946

NCT07214129

NCT03296670

NCT03158532

NCT07004764

NCT03059316

NCT04918563

NCT00493415

NCT02105493

NCT06637956

NCT00841594

NCT05239013

NCT02164318

NCT02265965

NCT01490073

NCT01901419

NCT01171170

NCT02714205

NCT01675700

NCT00431691

NCT01212874

NCT03481582

NCT03252665

NCT02688270

NCT02801305

NCT03622060

NCT00513994

NCT03408054

NCT04686760

NCT00616031

Known as Anrecta “The control patients self-administered topical glyceryl trinitrate, in the perianal area twice a day (Anrecta, Consentis Pharmaceuticals, Istanbul, Turkey)” NCT04320498
Known as Discotrine “INTERVENTION: The active drug was transdermal GN (Discotrine/Minitran, 3M Pharma) 15 mg/24 hours; placebo (PL) was an identical-looking patch applied before ERCP.” PMID 19410035 May 2009
Known as Glycerly Trinitrate Glycerly Trinitrate (Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal” NCT01811693
Known as glyceryl nitrate ClinicalTrials.gov intervention name — accepted as the source's own label NCT00121901
Known as glyceryl trinitrate “The central aim of this phase 2a study is to identify a regimen of paramedic initiated glyceryl trinitrate antihypertensive therapy in acute stroke patients that is safe, is...” NCT01811693
35

“Nitroglycerin, also known as glyceryl trinitrate (GTN), is a medication commonly used to treat heart conditions like angina pectoris and chronic heart failure.” NCT06925763

“0.4% Nitroglycerin ointment is an intra-anal formulation of nitroglycerin (glyceryl trinitrate) indicated for the treatment of chronic anal fissure pain.” PMID 16526822 2006

“The aim of this study was to compare the effect of transdermal nitroglycerin (glyceryl trinitrate, GTN) and oral nifedipine for managing preterm labor.” NCT02583633

Glyceryl trinitrate (GTN) induces migraine attacks indistinguishable from spontaneous attacks in approximately 80% of migraine sufferers.” NCT00257985

“The Effect of Glyceryl Trinitrate (GTN) and Diamox on Cerebral Haemodynamics Judged With the Help of 3-Tesla MRI.” NCT00363571

“Experimental and anecdotal evidence has supported the use of transdermal glyceryl trinitrate (GTN) patches.” PMID 27470183 Jul 2016

“Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: A randomized double-blind trial.” NCT00121901

“self-administered topical glyceryl trinitrate (anrecta), in the perianal area twice a day” NCT04320498

glyceryl trinitrate, beta-Blocking agent,etc” NCT03478332

NCT00700518

NCT04661709

NCT00479908

NCT06859554

NCT03787030

NCT02085213

NCT07044232

NCT05616455

NCT02499484

NCT04220606

NCT07159334

NCT00989716

NCT05687669

NCT00419549

NCT04766151

NCT04355598

NCT03251599

NCT02906553

NCT05635851

NCT02708251

NCT01132391

NCT01864252

NCT02495467

NCT00363792

NCT02700438

NCT03528772

Known as GTN “Eleven agents were used (nitroglycerin ointment (GTN), isosorbide dinitrate, Botulinum toxin (Botox), diltiazem, nifedipine (Calcium channel blockers or CCBs), hydrocortisone,...” PMID 17054170 Oct 2006
16

“The role of intravenous glyceryl trinitrate (GTN) therapy administered during cardiac surgery as a cardioprotective agent and whether it interferes with RIC cardioprotection is...” PMID 26412308 Sep 2015

“Glyceryl trinitrates (GTN) is infused to patients with severe hypertensive preeclampsia till oral anti-hypertensives and Magnesium sulfate loadings lower blood pressure” NCT05687669

“Nitroglycerin, also known as glyceryl trinitrate (GTN), is a medication commonly used to treat heart conditions like angina pectoris and chronic heart failure.” NCT06925763

“The aim of this study was to compare the effect of transdermal nitroglycerin (glyceryl trinitrate, GTN) and oral nifedipine for managing preterm labor.” NCT02583633

“Nitrates, such as glyceryl trinitrate (GTN), are drugs that release NO (NO donors) and are widely used in the treatment and prevention of angina.” NCT00479908

“Glyceryl trinitrate (GTN) induces migraine attacks indistinguishable from spontaneous attacks in approximately 80% of migraine sufferers.” NCT00257985

“Although the large Efficacy of Nitric Oxide in Stroke (ENOS) trial of transdermal glyceryl trinitrate (GTN) was neutral” PMID 26463698 Oct 2015

“Participants will apply 0.2% Glyceryl Trinitrate (GTN) ointment to the anal region twice daily for four weeks.” NCT06859554

“Experimental and anecdotal evidence has supported the use of transdermal glyceryl trinitrate (GTN) patches.” PMID 27470183 Jul 2016

“Glyceryl trinitrate (GTN) is a well-established cardiovascular medicine that is also a nitric oxide donor” PMID 32436761 May 2020

“Sublingual glyceryl trinitrate (GTN) has been shown to produce periampullary sphincter relaxation.” PMID 11531863 Sep 2001

“analgesic effect of glyceryl trinitrate cream (GTN) in reducing pain during IUD insertion” PMID 30898632 Mar 2019

“The most used experimental headache model is the glyceryl trinitrate model (GTN).” NCT00363571

“0.2% glyceryl trinitrate (GTN) ointment” NCT07159334

“the NO donor Glyceryl trinitrate (GTN)” NCT00363792

“Drug: Glyceryl trinitrate (GTN)” NCT04220606

Known as GTO “Glyceryl trinitrate ointment (GTO): Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were...” NCT03787030
Known as hydralizine hydralizineNCT00803634
Known as IMX-150 “A Randomized, Phase II, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Response Study of an Aqueous Topical Formulation of Nitroglycerin, IMX-150, in the Treatment of...” NCT00641953
Known as iNTG “The use of inhaled nitroglycerin (iNTG) as an alternative pulmonary vasodilator.” PMID 38490779 Dec 2023
Known as MED2005 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03813992
Known as Minitran “INTERVENTION: The active drug was transdermal GN (Discotrine/Minitran, 3M Pharma) 15 mg/24 hours; placebo (PL) was an identical-looking patch applied before ERCP.” PMID 19410035 May 2009
Known as MQX-303 “The purpose of this study is to determine, in comparison to a placebo control, the response to two dosage strengths of a topical gel formulation of nitroglycerin, MQX-303, in...” NCT00253331
Known as MQX-503 “The purpose of this clinical study is to determine, in a controlled fashion, the ability of a topical formulation of Nitroglycerin, MQX-503, to improve the patient's health...” NCT00577304
5

“A Study of a Topical Formulation of Nitroglycerin, Vascana® (MQX-503), and Matching Vehicle in the Treatment and Prevention of Symptoms Associated With Raynaud's Phenomenon” NCT00934427

“Phase III "In-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon” NCT00419419

“Phase III "in-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon” NCT00266669

“Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon” NCT00253331

“a fast acting topical formulation of Nitroglycerin, MQX-503NCT00480753

Known as MQX0503 “The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX0503) to relieve Raynaud's symptoms and...” NCT00577304
Known as MXQ-503 “nitroglycerin 0.9 % (MXQ-503)” NCT00841594
Known as Nitoglycerine-Glycerile Tinitrade “topical 0.2% GTN cream (Nitoglycerine-Glycerile Tinitrade 0.2%, 30 gm; E.S.A.G Pharma Co., Cairo, Egypt).” NCT03528772
Known as nitro glycerine “Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine )” NCT04594629
2

“Patients with PPHN will have nebulized nitroglycerine as adjunctive therapy” NCT05741229

“Topical Formulation of Nitroglycerine, Vascana®” NCT02688270

Known as Nitroderm “In the treatment group a nitroglycerin preparation (Nitroderm) was applied to the flap area.” PMID 21542401 Nov 2010
Known as Nitroglycerin tablets ClinicalTrials.gov intervention name — accepted as the source's own label NCT04270279
1

NCT04270071

Known as Nitrostat “Nitroglycerin (Nitrostat) is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.” NCT04008732
1

NCT01616485

Known as NNG “The objective was to evaluate the effect of nebulized nitroglycerin (NNG) in neonates with persistent pulmonary hypertension (PPHN).” PMID 40888971 Sep 2025
Known as NTG “RECTIV® is an ointment containing 0.4% nitroglycerin (NTG) for the treatment of moderate to severe pain associated with chronic anal fissure approved in June 2011 by the US...” NCT01920074
10

“OBJECTIVE: To determine whether uninterrupted administration of transdermal nitroglycerin (NTG) to induce nitrate cross-tolerance decreased the frequency or severity of...” PMID 37273224 Aug 2023

“Nitroglycerin (NTG) ointment is a potent topical vasodilator that increases local blood flow by dilating arteries and veins without altering the ratio of pre- to post-capillary...” NCT01608880

“Local nitroglycerin (NTG) was successfully used as a vasodilator to facilitate cannulation of the radial artery.” NCT04002544

“whether use of nitroglycerin (NTG) during CD has a protective effect.” PMID 27405400 Aug 2016

“nitroglycerin ointment (NTG) at 15 mg/day” NCT00252421

“glyceryl trinitrate (NTG, a NO donor)” NCT00419549

“Drug: Nitroglycerin (NTG)” NCT06682260

“Drug: Nitroglycerin (NTG)” NCT03357731

“Nitroglycerin (NTG)” NCT07083063

“Nitroglycerin (NTG)” NCT06637956

Known as Perlinganit “Nitroglycerin: (Perlinganit, Nycomet Heilmittelwerke, Vienna, Austria):” NCT00810381